Recent Updates
Recently added Catalysts

Mavrilimumab

Phase 2

COVID 19 | Small molecule | Infectious Disease |Kiniksa Pharmaceuticals International, plc|Last Updated: Jan 22, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment41
FDA Designations
No designations recorded
Clinical trial landscape

Mavrilimumab · 5 trials · 7 indications

Phase 2 5
NCT04463004Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCOVID-19
COMPLETED2 Analytics
NCT04399980Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCOVID 19
COMPLETED40 Analytics
NCT04492514Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationCOVID 19
COMPLETED1 Analytics
NCT04447469Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationCOVID
COMPLETED814 Analytics
NCT03827018KPL-301 for Subjects With Giant Cell ArteritisGiant Cell Arteritis
COMPLETED70 Analytics
PHASE2COMPLETED
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID-19Unlock trial analytics
PHASE2COMPLETED
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID 19Unlock trial analytics
PHASE2COMPLETED
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID 19Unlock trial analytics
PHASE2COMPLETED
Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
COVIDUnlock trial analytics
PHASE2COMPLETED
KPL-301 for Subjects With Giant Cell Arteritis
Giant Cell ArteritisUnlock trial analytics
Study Endpoints
Primary Endpoints
Proportion of Subjects Alive and Off of Oxygen at Day 14
14 days

Number of subjects alive and off of oxygen

Subjects Alive and Off of Oxygen at Day 14
Day 14

Number and percentage of subjects alive and off of oxygen at day 14

Proportion of Subjects Alive and Off Oxygen at 14 Days
14 days

Number of subjects alive and off of oxygen

Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29
Day 29

Mechanical ventilation is defined as invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Mechanical ventilation status was evaluated based on the National Institute of Allergy and Infectious Diseases (NIAID) clinical outcome 8-point ordinal scale. Participants whose clinical outcome met a NIAID score of 2 were considered as using mechanical ventilation. The NIAID score is an 8-point ordinal scale of clinical outcomes: 1=death; 2=hospitalized, on invasive mechanical ventilation or ECMO; 3=hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5=hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID 19 related or otherwise); 6=hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7=not hospitalized, limitation on activities and/or requiring home oxygen; 8=not hospitalized, no limitations on activities.

Cohort 1, Phase 3: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29
Day 29

Mechanical ventilation is defined as invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Mechanical ventilation status was evaluated based on the National Institute of Allergy and Infectious Diseases (NIAID) clinical outcome 8-point ordinal scale. Participants whose clinical outcome met a NIAID score of 2 were considered as using mechanical ventilation. The NIAID score is an 8-point ordinal scale of clinical outcomes: 1=death; 2=hospitalized, on invasive mechanical ventilation or ECMO; 3=hospitalized, on non-invasive ventilation or high flow oxygen devices; 4= hospitalized, requiring supplemental oxygen; 5=hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID 19 related or otherwise); 6=hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7=not hospitalized, limitation on activities and/or requiring home oxygen; 8=not hospitalized, no limitations on activities.

Cohort 2, Phase 2: Percentage of Participants Who Died by Day 29
Day 29

Defined as the proportion of subjects with mechanical ventilation who have died by Day 29.

Cohort 2, Phase 3: Percentage of Participants Who Died by Day 29
Day 29

Defined as the proportion of subjects with mechanical ventilation who have died by Day 29.

Time to Flare by Week 26
Week 26

Time to flare by Week 26 was defined as time from randomization to the date of first flare occurring within the 26-week period, as assessed by independent adjudication. Kaplan-Meier method used to estimate the survival functions for each treatment arm. Flare/relapse was defined as a C-reactive protein (CRP) of 1 mg/dL or greater and/or erythrocyte sedimentation rate (ESR) of 30 mm/h or greater AND at least one of the following signs or symptoms attributed to GCA: Cranial symptoms (new-onset localized headache; scalp or temporal artery tenderness; ischemic-related vision loss; unexplained mouth or jaw pain upon mastication; transient ischemic attack or stroke related to GCA); Extracranial symptoms (claudication of the extremities; symptoms of polymyalgia rheumatica); New or worsening angiographic abnormalities detected via MRI, CT/CTA, or PET-CT of the aorta or other great vessels or via ultrasound of the temporal arteries.

Secondary Endpoints
Number of Subjects Alive and Without Respiratory Failure at 28 Days
28 days
Number of Subjects Alive and Without Respiratory Failure at Day 28
Day 28
Mortality at Day 28
Day 28
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelFACTORIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
InterventionACTIVE_COMPARATORTreatment infusion
ControlPLACEBO_COMPARATORPlacebo infusion
MavrilimumabEXPERIMENTALMavrilimumab Treatment infusion
PlaceboPLACEBO_COMPARATORPlacebo infusion
10 mg/kg (Cohort 1)ACTIVE_COMPARATORNon-mechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
6 mg/kg (Cohort 1)ACTIVE_COMPARATORNon-mechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
Placebo (Cohort 1)PLACEBO_COMPARATORNon-mechanically ventilated participants administered placebo as a single IV infusion
10 mg/kg (Cohort 2)ACTIVE_COMPARATORMechanically ventilated participants administered mavrilimumab 10 mg/kg as a single IV infusion
6 mg/kg (Cohort 2)ACTIVE_COMPARATORMechanically ventilated participants administered mavrilimumab 6 mg/kg as a single IV infusion
Placebo (Cohort 2)PLACEBO_COMPARATORMechanically ventilated participants administered placebo as a single IV infusion
Interventions
NameTypeDescription
MavrilimumabDRUGTreatment infusion
PlacebosDRUGPlacebo infusion
PlaceboDRUGPlacebo infusion
prednisoneDRUGPrednisone tablets for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone United States Pharmacopeia (USP)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed 2. Documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/ infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongo...

Countries:United StatesBrazilChilePeruSouth AfricaAustraliaBelgiumCroatiaEstoniaGermanyIrelandItalyNetherlandsNew ZealandPolandSerbiaSloveniaSpainUnited Kingdom
Unlock Eligibility Criteria